Alkem Q1FY27: consolidated PAT down 22% YoY on tax-regime reset, PBT nearly flat
PAT -21.99% YoY · revenue +10.95% · margins compressing
₹3,740.15 Cr
+10.95% YoY
₹520.98 Cr
-21.99% YoY
13.38%
-5.7pp YoY
₹43.49
Alkem's consolidated PAT fell 22.0% YoY to Rs520.98 Cr in Q1 FY27 (quarter ended 30 June 2026), even as revenue from operations grew a healthy 10.95% YoY to Rs3,740.15 Cr and consolidated PBT was essentially flat (Rs771.99 Cr vs Rs771.01 Cr a year earlier, +0.1%). The gap between flat pretax profit and a sharply lower bottom line is explained almost entirely by tax: the effective tax rate jumped to 32.5% this quarter from 13.3% in Q1 FY26, after the company moved to the new tax regime under Section 115BAA of the Income-tax Act (Note 4) - deferred tax is now recognised at the new regime's enacted rates, ending the more favourable MAT-credit treatment used earlier. Standalone PAT of Rs569.98 Cr was down a smaller 13.1% YoY on 12.5% revenue growth to Rs2,667.73 Cr - a divergence of more than 3 points from the consolidated decline, stemming from subsidiary-level tax, NCI and associate dynamics that don't touch the parent-only numbers. Neither statement carries an exceptional item this quarter; a year ago the consolidated result had booked a small Rs12.93 Cr one-off gain from the Indore facility sale, so the adjusted YoY PAT decline (~20.5%) is only marginally softer than the reported -22.0%.
Q1 FY-2027 vs prior quarters
Margins compressed on a YoY basis even before the tax effect. Core pre-exceptional profitability (PBT before exceptional items as a share of total income) slipped to 19.83% from 21.62% a year ago, as employee benefits expense rose 16.7% YoY (Rs808.90 Cr vs Rs693.25 Cr) and finance costs nearly doubled (+56.6% YoY, Rs46.62 Cr vs Rs29.78 Cr), both outpacing the 10.95% topline growth. Net margin (PAT/total income) fell to 13.4% from 19.0% YoY. Sequentially, PAT more than doubled (+107.5% QoQ) against Q4 FY26's Rs251.11 Cr, but that base was itself depressed by a Rs134.97 Cr net exceptional charge (a Rs74.7 Cr real-estate impairment provision plus a Rs60.27 Cr gratuity/leave-encashment liability under the new Labour Codes) - so the QoQ jump is a base-effect artefact rather than fresh operating momentum and should not be read as a trend.
The stock went into the print at ₹5,417, down 5.1% over the past month of trading.
What the summary numbers don't show
EPS: consolidated Rs43.49 (vs Rs55.56 YoY, Rs19.77 QoQ) — standalone Rs47.67 (vs Rs52.04 YoY, Rs18.16 QoQ).
Alkem Laboratories is projecting continued strong growth in FY27, with the India business expected to grow 100-150 basis points above market rates, driven by key therapies and new launches like semaglutide. The US business is anticipated to achieve high single-digit growth on a dollar-to-dollar basis, potentially boost
— This quarter: met
We could not find reliable analyst consensus estimates specifically previewing this Q1 FY27 print, so the vs-street read is unknown rather than assumed. Against management's own FY27 outlook from the May 2026 call - a 20-21% margin target, India growth 100-150bps above market, US high-single-digit dollar growth, and ROW higher-teens growth - this filing (single-segment disclosure, no India/US/ROW split) only lets us check the margin line: core pre-exceptional margin of ~19.8% sits just under the guided band, so the quarter reads as broadly on track rather than a clear beat or miss. Alkem issued no accompanying press-release commentary with this filing (none extracted for this result), so there is no fresh management framing to reconcile against the numbers. Two corporate developments bracket this print: Alkem Medtech completed its majority-stake acquisition of Switzerland's Occlutech Holding AG on 16 July 2026 (Note 5) - after the reporting quarter, so it has no impact on these numbers but enters consolidation from Q2 FY27; and a company facility was placed under USFDA OAI status on 6 August 2026, a regulatory flag that doesn't show up in this quarter's P&L but is worth tracking for supply continuity.
W1
FY27 margin trajectory vs management's 20-21% target - core PBT margin was ~19.8% this quarter, still just under the guided band.
W2
Whether the ~32.5% effective tax rate (new 115BAA regime) persists through FY27 or eases as the transition beds in.
W3
Occlutech integration entering consolidation from Q2 FY27, and remediation status/impact from the 6 Aug 2026 USFDA OAI flag at an Alkem facility.
Mid-year tracking: margin defense amid FDA headwinds
With the FDA inspection fallout still settling, focus turns to whether Alkem can sustain its US momentum and deliver on FY27 guidance — Q1 is a key read for the growth and margin story.
What to Expect
~₹550-600 Cr
Mid-year typical; US segment the swing factor — 40%+ of revenue
~20-21%
In-line with FY27 guidance; Medtech losses offset by core generics strength
~₹120-135 Cr
Normal run-rate; prior year benefited from tax wins (not repeating)
A strong Q1 print would show: revenue growth in the low double digits YoY (12-15% range), margins holding the 20-21% band despite Medtech drag, and credible FDA remediation clarity (timeline and confidence on the April-May OAI observations). A weak print would flag: revenue miss (sub-10% growth), margin compression below 20%, vague FDA commentary, or binding cautions on production capacity or shipment continuity.
On Track?
FY26 ended at ₹2,308 Cr revenue; FY27 guidance is embedded in the 20-21% EBITDA margin signal, implying steady growth with operational leverage. Q1 is mid-year and should confirm whether the US rebound (which drove Q4 FY26) is sustaining. The Occlutech acquisition (closed July 2026) is non-consolidated for now; Medtech losses (₹40-50 Cr annually through FY28) are a known drag on reported margin. Watch for cash deployment and integration ramp in Q1.
What the Street Says
Since Last Quarter
1 · FDA OAI Status (Aug 6) — Amaliya, Daman
Facility received Official Action Indicated status following April 20–May 1, 2026 inspection. Seven FDA 483 observations noted on Form FDA 483. OAI status means the FDA will halt new ANDA approvals until observations are remediated. Material compliance risk — no timeline or severity disclosed yet; this dominates the pre-result narrative and will be the first Q&A on the call.
2 · Occlutech Acquisition Completed (Jul 17)
Wholly-owned Alkem Medtech acquired Occlutech Holding AG (Swiss medical device company). Capex and losses of ₹40-50 Cr annually through FY27; targeting Medtech breakeven by FY28. Q1 consolidation will reflect the first month of Occlutech contribution.
3 · Semaglutide Launch (Jun 2) — Specialty Play
First-to-market in India: single-shot pre-filled syringes at ₹350. Addresses diabetes/obesity space — large TAM but nascent penetration. Q1 revenue contribution minimal; upside story for FY27-FY28 as awareness ramps.
4 · Tax Win ₹660.77 Cr (Jul 1) — Non-Repeating
Favorable orders-in-appeal from CoIT Mumbai (AY 2018-19 to 2022-23) for disallowance deletions. One-time positive; reduces effective tax rate for the reported P&L but won't repeat. Mark as non-operating.
5 · Management Reshuffle (Aug 3 & Jul 23)
Rajpal Singh Rana (30+ years marketing/sales) appointed to senior management (Aug 3). Dr. Jitendra Singh Huda resigned seeking other opportunities (Jul 23). Scale-routine, but signals leadership changes — watch for strategy commentary on the call.
6 · Merger/Amalgamation Scheme Approval (Aug 17)
Shareholder meeting Aug 17 to approve scheme of amalgamation; details sparse. Likely Medtech consolidation; await disclosures for impact clarity.
On Result Day (Aug 14)
1 · FDA Remediation Plan & Timelines
Management must address Amaliya OAI: timeline to remediation submission, confidence level in re-approval, any production line halt/impact, and export/shipment continuity. This single item will move the stock 2-3%+ and will dominate the call.
2 · US Revenue & Realization Trends
Generics + specialty growth YoY; pricing/volume mix; competitive share trends. US is 40%+ of revenue and the growth engine — softness here signals broader execution risk.
3 · FY27 Guidance — Reconfirmed?
Will management stand by 20-21% EBITDA margin guidance for FY27? Any update on revenue growth expectations or Medtech loss assumptions? This frames the full-year narrative.
4 · Occlutech Integration & Medtech Losses
Q1 will consolidate the first month of Occlutech. Are losses tracking the ₹40-50 Cr annual guidance? Any surprise upside/downside? Monitor cash burn assumptions.
Alkem reports Q1 FY27 on August 14 at an inflection: the FDA compliance issue is now live (OAI status is material), the medtech transition is underway (Occlutech closed), and the core generics + specialty business must prove resilience. The stock, near consensus target (₹5,535) and neutral on technicals (RSI 48), will respond sharply to three data points: (1) credible FDA remediation timelines and confidence, (2) US generics growth holding double-digit pace, and (3) reconfirmed FY27 margin guidance. A clean quarter with transparent FDA commentary could support the Nomura/ICICI upsides; any miss or vague guidance tilts the needle toward Jefferies' downside caution.